Rilonacept, on the other hand, blocks IL-1 signaling by acting as a soluble decoy receptor that binds both IL-1α and IL-1β, thus preventing their interplay with cell surface receptors, disrupting the cycle of autoinflammation encountered in recurrent pericarditis, at least in some cases [75]. This evidence concerns the gene IL1A and pericarditis.